The FDA approved zanubrutinib, a second-generation Bruton’s tyrosine kinase inhibitor. The U.S. Food and Drug Administration (FDA) has approved zanubrutinib (Brukinsa) for the treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ...
Women over 65 are diagnosed at later stages of cervical cancer, and other stories from this week in cancer news, selected by the editors of Cancer Today.
A new immunotherapy targets six different viruses that can cause infections when the immune system is suppressed to allow potentially life-saving transplants, according to trial results published in the AACR journal Clinical Cancer Research.
Therapeutic antibodies carry ‘payloads’ to destroy cancer cells.
Neurologist David Schiff discusses the significance of new evidence-based guidance on how to treat brain metastases from solid tumors.
Cardiovascular mortality rates for survivors of early-stage Hodgkin lymphoma outpace cancer-related mortality.
Cancer patients have an increased risk of breakthrough COVID-19 infections, and more of the top stories in cancer news selected by the editors of Cancer Today.
Technology could help detect lymphedema earlier.
Remote approaches would remove barriers, potentially improving patient participation and diversity.
Low- and middle-income countries make inroads against a preventable and treatable cancer.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now